Monitoring antimicrobial resistance in the Democratic Republic of Congo
Official title: Surveillance of Antimicrobial Resistance in Semirural Kinshasa, Democratic Republic of Congo: a Feasibility Study
Run by University of Oxford · NCT06821282 · Data updated 2026-11-12
This study is testing how well we can track antibiotic resistance in a hospital in Kinshasa, DRC, to better understand bacterial infections and improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Months and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Kinshasa, Kinshasa City) |
| Status | Recruiting |
| Started | November 11, 2024 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT06821282 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients over six months old presenting with suspected bloodstream infections upon hospital admission.
✕Probably not a fit
Patients with significant prior healthcare exposure or contraindications for phlebotomy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to fill knowledge gaps regarding antimicrobial resistance (AMR) in sub-Saharan Africa by evaluating the feasibility of AMR surveillance in a general referral hospital in semirural Kinshasa, DRC. It will investigate bacterial infections, their resistance profiles, and associated risk factors, including co-infections like malaria. The study involves training local staff in patient identification and specimen collection for AMR surveillance, with blood samples analyzed to determine bacterial causes of infections and resistance levels. Participants will be followed for 28 days post-admission to assess outcomes and improve patient management.
Why it matters
Potential benefit: If successful, this study could enhance understanding and management of antimicrobial resistance, leading to better treatment outcomes for patients with bloodstream infections.
How similar studies have gone: While AMR surveillance has been studied in various contexts, this specific approach in semirural DRC is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Patients older than six months who present with a clinically suspected bloodstream infection upon admission to the hospital, or who have been hospitalized for less than 48 hours, and provide written consent (or consent from their caregiver/legal guardian) to participate will be included. Patients with a significant history of healthcare exposure and those with any contraindications for phlebotomy as determined by the clinician's judgment, will be excluded.
Where it's running
-
Kinshasa, Democratic Republic of Congo, Kinshasa School of Public Health
Kinshasa, Kinshasa City, Democratic Republic of the Congo Recruiting
Study contacts
- Principal investigator: Caterina Fanello, Dr. — Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom (UK)
- Study coordinator: Caterina Fanello, Dr.
- Email: caterina.fanello@ndm.ox.ac.uk
- Phone: +447900278768
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
UllCORE BSI Test for Bloodstream Infections
This study tests whether the UllCORE BSI Test can correctly detect bloodstream infection pathogens and resistance markers from whole blood in people with suspected infection or sepsis.
-
Beta-lactam plus levofloxacin for streptococcal bacteremia
This trial tests whether adding levofloxacin to standard beta-lactam therapy helps adults with streptococcal bacteremia see better outcomes.
-
Blood cultures from arterial lines: does it change contamination, bacteremia detection, and how much blood is drawn?
This study tests whether drawing blood cultures from arterial lines affects contamination rates, how well bacteremia is detected, and the volume of blood collected in ICU patients.
-
New care guideline for infants 60 days and younger with fever in Sweden
This project will test a new guideline to see if infants 60 days or younger with fever can safely avoid many invasive tests, hospital stays, and broad antibiotics compared with usual care.
-
GRADY: a computer tool to detect early sepsis and gram-negative bloodstream infection in ICU patients
The GRADY tool will be tested to see if routine vital signs and lab results can detect early sepsis and gram-negative bloodstream infection in adult ICU patients.
-
Linezolid added to standard care for Staphylococcus aureus bloodstream infection
This trial will test whether giving linezolid in addition to usual antibiotics helps adults hospitalized with Staphylococcus aureus bloodstream infections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.